title: Clinical Assessment of a Novel Jasmonate Cosmeceutical, LR2412-Cx, for the Treatment of Skin Aging.
abstract: BACKGROUND
  The jasmonates are a novel class of plant-derived anti-aging compounds. Among these, LR2412-Cx (tetrahydrojasmonic acid, Visionnaire) has been demonstrated to reduce photoaging and the appearance of wrinkles, as well as to upregulate collagens, hyaluronic acid and fibrillin.
  
  
  OBJECTIVE
  To clinically study the cosmetic effects of a novel jasmonate complex LR2412-Cx in the treatment of visible skin aging.
  
  
  METHODS
  LR2412-Cx was evaluated in a 15-subject open-label prospective clinical trial for the treatment of fine wrinkle appearance, texture, and pores. Subjects were evaluated by an investigator at baseline, day 1, day 3, and week 6 with the Alexiades comprehensive grading scale of skin aging, and introducing a novel pore-grading scale and subject quality of life assessments.
  
  
  RESULTS
  The mean (SEM) at baseline and at week 6 following twice-daily application were: for the appearance of wrinkles 2.91 (0.12) and 2.70 (0.10); for texture 2.91 (0.10) and 2.55 (0.10); and for pores 3.29 (0.08) and 2.46 (0.09), respectively. The differences in all 3 categories at all follow-up intervals were statistically significant (P<.005). The percentage improvement in investigator-assessed grades relative to baseline at day 1, day 3, and week 6 were: 2.3%, 4.9%, and 7.4% for the appearance of wrinkles, 5.7%, 9.4%, and 12.4% for texture, and 14.2%, 21.6% and 25.2% for pores, respectively. No significant untoward effects were reported.
  
  
  CONCLUSIONS
  Visionnaire LR2412-Cx is a novel jasmonate-containing compound that is safe and effective for the cosmetic treatment of fine wrinkle appearance, texture, and pores of the facial skin.
authors.forename: Macrene
authors.initials: M
authors.lastname: Alexiades
mesh_terms: D000279:Administration, Cutaneous; D000328:Adult; D000068937:Cosmeceuticals / Q000008:administration & dosage*; D003517:Cyclopentanes / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D054883:Oxylipins / Q000008:administration & dosage*; D011446:Prospective Studies; D015595:Skin Aging / Q000187:drug effects* / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000068937:Cosmeceuticals; D003517:Cyclopentanes; D054883:Oxylipins; C000593049:tetrahydrojasmonic acid; C011006:jasmonic acid